AR046620A1 - Pentafluorosulfanilbenzoilguanidinas, procedimiento para su preparacion, su uso como medicamento o coadyuvante de diagnostico, y medicamento que las comprende - Google Patents

Pentafluorosulfanilbenzoilguanidinas, procedimiento para su preparacion, su uso como medicamento o coadyuvante de diagnostico, y medicamento que las comprende

Info

Publication number
AR046620A1
AR046620A1 ARP040104156A ARP040104156A AR046620A1 AR 046620 A1 AR046620 A1 AR 046620A1 AR P040104156 A ARP040104156 A AR P040104156A AR P040104156 A ARP040104156 A AR P040104156A AR 046620 A1 AR046620 A1 AR 046620A1
Authority
AR
Argentina
Prior art keywords
zero
alkyl
hydrogen
alkoxy
substituted
Prior art date
Application number
ARP040104156A
Other languages
English (en)
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of AR046620A1 publication Critical patent/AR046620A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C381/00Compounds containing carbon and sulfur and having functional groups not covered by groups C07C301/00 - C07C337/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0404Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0406Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)

Abstract

Son adecuados, por ejemplo, como medicamentos antiarrítmicos con un componente cardioprotector para la profilaxis del infarto y el tratamiento del infarto y para el tratamiento de la angina de pecho. También inhiben de forma preventiva los procesos patofisiológicos asociados con el desarrollo de lesiones inducidas por isquemia, especialmente en el desencadenamiento de arritmias cardíacas inducidas por isquemia. Reivindicación 1: Un compuesto de la fórmula (1), en la que: R1 es hidrógeno, alquilo C1-4, alcoxi C1-4, F, Cl, Br, I, -CN, NR5R6, -Op-(CH2)n-(CF2)o-CF3 o -(SOm)q-(CH2)r-(CF2)s-CF3; R5 y R6 son, independientemente uno de otro, hidrógeno, alquilo C1-4 o -CH2-CF3; m es cero, 1 ó 2; n, o, p, q, r y s son, independientemente uno de otro, cero ó 1; R2 es hidrógeno, alquilo C1-4, alcoxi C1-4, F, Cl, Br, I, -CN, NR7R8, -Ot-(CH2)u-(CF2)v-CF3 o -(SOw)x-(CH2)y-(CF2)z-CF3; R7 y R8 son, independientemente uno de otro, hidrógeno, alquilo C1-4 o -CH2-CF3; m es cero, 1 ó 2; t, u, v, w, x, y y z son, independientemente uno de otro, cero ó 1; R3 es Cl, Br, I, -CN, -SO2CH3, alcoxi C1-4, NR9R10, -Oa-(CH2)b-(CF2)c-CF3, -(SOd)e-(CH2)f-(CF2)g-CF3, alquilo C1-6 o cicloalquilo C3-8, en que 1, 2, 3 ó 4 átomos de hidrógeno pueden estar reemplazados por átomos de flúor; R9 y R10 son, independientemente uno de otro, hidrógeno, alquilo C1-4 o -CH2-CF3; a, b y c son, independientemente uno de otro, cero ó 1; d es cero, 1 ó 2; e es cero ó 1; f es cero, 1, 2, 3 ó 4; g es cero ó 1; o R3 es -(CH2)h-fenilo o -O-fenilo, en que los radicales fenilo no están sustituidos o están sustituidos con 1, 2 ó 3 radicales seleccionados del grupo que consiste en F, Cl, Br, I, -Oj-(CH2)k-CF3, alcoxi C1-4, alquilo C1-4, y -SO2CH3; j es cero ó 1; k es cero, 1, 2 ó 3; h es cero, 1, 2, 3 ó 4; o R3 es -(CH2)aa-heteroarilo, que no está sustituido o está sustituido con 1, 2 ó 3 radicales seleccionados del grupo que consiste en F, Cl, Br, I, -Obb-(CH2)cc-CF3, alcoxi C1-4 y alquilo C1-4 y -SO2CH3; bb es cero ó 1; cc es cero, 1, 2 ó 3; aa es cero, 1, 2, 3 ó 4; R4 es hidrógeno, F, Cl, Br, I, -CN, -SO2CH3, alcoxi C1-4, NR11R12, -Odd-(CH2)ee-(CF2)ff-CF3, -(SOgg)hh-(CH2)jj-(CF2)kk-CF3, alquilo C1-6 o cicloalquilo C3-8, en que 1, 2, 3 ó 4 átomos de hidrógeno pueden estar reemplazados por átomos de flúor; R11 y R12 son, independientemente uno de otro, hidrógeno, alquilo C1-4 o -CH2-CF3; dd, ee y ff son, independientemente uno de otro, cero ó 1; gg es cero, 1 ó 2; hh es cero ó 1; jj es cero, 1, 2, 3 ó 4; kk es cero ó 1; o R4 es -(CH2)ll-fenilo o -O-fenilo, en que los radicales fenilo no están sustituidos o están sustituidos con 1, 2 ó 3 radicales seleccionados del grupo que consiste en F, Cl, Br, I, -Omm-(CH2)nn-CF3, alcoxi C1-4, alquilo C1-4 y -SO2CH3; mm es cero ó 1; nn es cero, 1, 2 ó 3; ll es cero, 1, 2, 3 ó 4; o R4 es -(CH2)oo-heteroarilo, que no está sustituido o está sustituido con 1, 2 ó 3 radicales seleccionados del grupo que consiste en F, Cl, Br, I, -Opp-(CH2)rr-CF3, alcoxi C1-4 y alquilo C1-4 y -SO2CH3; pp es cero ó 1; rr es cero, 1, 2 ó 3; oo es cero, 1, 2, 3 ó 4; y sus sales farmacéuticamente aceptables.
ARP040104156A 2003-11-13 2004-11-11 Pentafluorosulfanilbenzoilguanidinas, procedimiento para su preparacion, su uso como medicamento o coadyuvante de diagnostico, y medicamento que las comprende AR046620A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10353202A DE10353202A1 (de) 2003-11-13 2003-11-13 Pentafluorsulfuranyl-benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament

Publications (1)

Publication Number Publication Date
AR046620A1 true AR046620A1 (es) 2005-12-14

Family

ID=34585094

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040104156A AR046620A1 (es) 2003-11-13 2004-11-11 Pentafluorosulfanilbenzoilguanidinas, procedimiento para su preparacion, su uso como medicamento o coadyuvante de diagnostico, y medicamento que las comprende

Country Status (39)

Country Link
EP (1) EP1685096B1 (es)
JP (1) JP4528304B2 (es)
KR (1) KR101262065B1 (es)
CN (1) CN100445265C (es)
AR (1) AR046620A1 (es)
AT (1) ATE368029T1 (es)
AU (1) AU2004288758B2 (es)
BR (1) BRPI0416487A (es)
CA (1) CA2551057C (es)
CR (1) CR8321A (es)
CY (1) CY1106868T1 (es)
DE (2) DE10353202A1 (es)
DK (1) DK1685096T3 (es)
DO (1) DOP2004001028A (es)
EC (1) ECSP066563A (es)
ES (1) ES2287788T3 (es)
GT (1) GT200400217A (es)
HK (1) HK1095584A1 (es)
HN (1) HN2004000474A (es)
HR (1) HRP20070364T3 (es)
IL (1) IL175237A (es)
JO (1) JO2466B1 (es)
MA (1) MA28161A1 (es)
MY (1) MY144211A (es)
NI (1) NI200600112A (es)
NO (1) NO20062635L (es)
NZ (1) NZ547172A (es)
OA (1) OA13285A (es)
PE (1) PE20051034A1 (es)
PL (1) PL1685096T3 (es)
PT (1) PT1685096E (es)
RS (1) RS50520B (es)
RU (1) RU2380358C2 (es)
TN (1) TNSN06116A1 (es)
TW (1) TWI334411B (es)
UA (1) UA84307C2 (es)
UY (1) UY28616A1 (es)
WO (1) WO2005047239A1 (es)
ZA (1) ZA200602579B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7317124B2 (en) * 2003-11-13 2008-01-08 Sanofi-Aventis Deutschland Gmbh Ortho-substituted pentafluorosulfanylbenzenes, process for their preparation and their use as valuable synthetic intermediates
WO2009097972A1 (de) 2008-02-05 2009-08-13 Sanofi-Aventis Sf5-derivate als par1-inhibitoren, ihre herstellung und verwendung als arzneimittel
EP2661434A4 (en) * 2011-01-06 2014-07-09 Beta Pharma Canada Inc NEW URGES FOR THE TREATMENT AND PREVENTION OF CANCER
EP3064489A4 (en) 2013-11-01 2017-06-21 Ube Industries, Ltd. Aryloyl(oxy or amino)pentafluorosulfanylbenzene compound, pharmaceutically acceptable salt thereof, and prodrugs thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2097409T3 (es) * 1992-09-22 1997-04-01 Hoechst Ag Benzoilguanidinas, procedimiento para su preparacion, asi como su empleo como antiarritmicos.
DE4417004A1 (de) * 1994-05-13 1995-11-16 Hoechst Ag Perfluoralkyl-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19517848A1 (de) * 1995-05-16 1996-11-21 Merck Patent Gmbh Fluorhaltige Benzoylguanidine
DE19526381A1 (de) * 1995-07-19 1997-01-23 Hoechst Ag 4-Fluoralkyl-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19713427A1 (de) * 1997-04-01 1998-10-08 Hoechst Ag Ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19950898A1 (de) * 1999-10-22 2001-04-26 Aventis Pharma Gmbh Heterocyclisch substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE10222192A1 (de) * 2002-05-18 2003-11-27 Aventis Pharma Gmbh Pentafluorsulfuranyl-benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE10338554A1 (de) * 2003-08-22 2005-03-31 Aventis Pharma Deutschland Gmbh Pentafluorosulfanylphenyl-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament

Also Published As

Publication number Publication date
JP2007513076A (ja) 2007-05-24
BRPI0416487A (pt) 2007-03-27
NI200600112A (es) 2006-12-12
OA13285A (en) 2007-01-31
ES2287788T3 (es) 2007-12-16
CY1106868T1 (el) 2012-09-26
NO20062635L (no) 2006-08-11
AU2004288758B2 (en) 2011-06-02
ATE368029T1 (de) 2007-08-15
CR8321A (es) 2007-09-14
CA2551057A1 (en) 2005-05-26
MY144211A (en) 2011-08-15
DK1685096T3 (da) 2007-10-22
DOP2004001028A (es) 2005-05-14
AU2004288758A1 (en) 2005-05-26
HK1095584A1 (en) 2007-05-11
EP1685096B1 (de) 2007-07-25
HRP20070364T3 (en) 2008-01-31
ZA200602579B (en) 2007-06-27
EP1685096A1 (de) 2006-08-02
RU2380358C2 (ru) 2010-01-27
CN100445265C (zh) 2008-12-24
WO2005047239A1 (de) 2005-05-26
KR20060122848A (ko) 2006-11-30
PE20051034A1 (es) 2005-12-23
RS50520B (sr) 2010-05-07
TW200530162A (en) 2005-09-16
DE10353202A1 (de) 2005-06-16
RU2006120448A (ru) 2007-12-27
DE502004004460D1 (de) 2007-09-06
CN1878755A (zh) 2006-12-13
IL175237A (en) 2010-12-30
UA84307C2 (ru) 2008-10-10
MA28161A1 (fr) 2006-09-01
UY28616A1 (es) 2005-06-30
IL175237A0 (en) 2006-09-05
ECSP066563A (es) 2006-10-17
KR101262065B1 (ko) 2013-05-08
JP4528304B2 (ja) 2010-08-18
TWI334411B (en) 2010-12-11
NZ547172A (en) 2009-12-24
TNSN06116A1 (en) 2007-11-15
PT1685096E (pt) 2007-09-04
PL1685096T3 (pl) 2007-11-30
HN2004000474A (es) 2009-06-19
JO2466B1 (en) 2009-01-20
GT200400217A (es) 2005-06-23
CA2551057C (en) 2012-10-30

Similar Documents

Publication Publication Date Title
AR048039A1 (es) Profarmacos de piperazina y agentes antivirales de piperidina sustituidos
AR058379A1 (es) Derivados de arilpropionamida arilacrilamida arilpropinamida o arilmetilurea como inhibidores del factor xia. proceso de obtencion y composiciones farmaceuticas.
CO2019011604A2 (es) Compuestos inhibidores de vmat2, composiciones y métodos relativos a los mismos
RU2015148010A (ru) Высокоактивное производное нуклеозида для лечения hcv
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
AR064304A1 (es) Formulaciones de ansamicina y sus metodos de uso
AR067759A1 (es) Compuestos de pirazol utiles como moduladores de la enzima raf asociada al crecimiento celular anormal
AR074543A1 (es) Derivados de imidazo[1,2-a]piridin-2-il, agonistas de receptores 1-fosfato de esfingosina(1s1p1), composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos en el tratamiento de enfermedades autoinmunes
PA8580301A1 (es) Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
AR054482A1 (es) Derivados de azetidinona para el tratamiento de hiperlipidemias
DOP2002000422A (es) Agentes antibacterianos.
PA8574701A1 (es) Derivados de isoindolona, proceso de preparacion y compuestos intermedios de este proceso, su uso como medicamentos, y composiciones farmaceuticas que los contienen
AR031226A1 (es) 1,1'-bifenil-2-carboxamidas 2'-sustituidas, procesos para su preparacion, su uso para la manufactura de un medicamento, y composiciones farmaceuticas que las contienen
AR074352A1 (es) Acidos naftalen-2-il-aceticos sustituidos, composiciones farmaceuticas que los contienen, y uso de los mismos en el tratamiento de enfermedades alergicas,tales como rinitis, asma y dermatitis atopica.
ECSP044999A (es) Agentes antidiabeticos
AR039689A1 (es) Difenilazetidinonas sustituidas, medicamentos que comprenden estos compuestos y su uso
CO6690783A2 (es) Combinaciones que contienen n-(2-arilamino)arilsulfonamida sustituida
CO2021017435A2 (es) Analogos de 3–(5–metil–1,3–tiazol–2–il)–n–{(1r)–1–[2–(trifluor–metil)pirimidin–5–il]etil}benzamida
UY27685A1 (es) Indolil-urea derivados de tienopiridinas útiles como agentes antiangiogénicos, y procedimientos para su uso
AR043444A1 (es) Profarmacos de diaril-2- 5h -furanonas que liberan oxido nitrico como inhibidores de la ciclooxigenasa-2
CY1115377T1 (el) Παραγωγο αζωτουχου αρωματικου 6-μελους δακτυλιου και φαρμακευτικος παραγων που περιλαμβανει αυτο
AR046620A1 (es) Pentafluorosulfanilbenzoilguanidinas, procedimiento para su preparacion, su uso como medicamento o coadyuvante de diagnostico, y medicamento que las comprende
AR074700A1 (es) Derivados heterociclicos fusionados con oxadiazola, composiciones farmaceuticas, procesos de preparacion y su uso en el tratamiento de esclerosis multiple y otras enfermedades
UY29394A1 (es) Derivados sustituidos de n-(5-(2-propilamino.1.hidroxietil)-2-hdroxifenil) metano sulfonamida, composiciones farmacéuticas que lo contienen y aplicaciónes.
AR039401A1 (es) Un compuesto antagonista de integrinas alfa 4 y un procedimiento para preparar el mismo

Legal Events

Date Code Title Description
FA Abandonment or withdrawal